SQUIRE: A randomized, multicenter, open-label, phase III, controlled trial for first-line treatment of metastatic squamous NSCLC (N=1093)1

SQUIRE trial design1,2

SQUIRE trial design chart
Zoom In
Zoom Out

*Investigator assessed.

  • Patients demonstrating at least stable disease on Portrazza plus gemcitabine and cisplatin were to continue Portrazza as a single agent in the absence of disease progression or unacceptable toxicity after completion of 6 planned courses of chemotherapy or if chemotherapy was discontinued for toxicity1
  • In the Portrazza plus gemcitabine and cisplatin arm, 51% of patients continued Portrazza after completion or discontinuation of chemotherapy1
  • The median duration of exposure to Portrazza in 538 patients who received at least 1 dose of treatment in SQUIRE was 4.6 months (range 0.5 months to 34 months), including 182 (33.8%) patients exposed for at least 6 months and 41 (7.6%) exposed for >1 year1

NSCLC=non-small cell lung cancer; ECOG=Eastern Cooperative Oncology Group; PS=performance status; q3w=every 3 weeks; IV=intravenous; D=day; CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease; PFS=progression-free survival; ORR=overall response rate.

References: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015. 2. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774.